Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission.

MLA

Shadman, Mazyar, et al. “Autologous Transplant vs. CAR-T Therapy in Patients with DLBCL Treated While in Complete Remission.” Blood Cancer Journal, vol. 14, no. 1, July 2024, pp. 1–7. EBSCOhost, https://doi.org/10.1038/s41408-024-01084-w.

APA

Shadman, M., Ahn, K. W., Kaur, M., Lekakis, L., Beitinjaneh, A., Iqbal, M., Ahmed, N., Hill, B., Hossain, N. M., Riedell, P., Gopal, A. K., Grover, N., Frigault, M., Brammer, J., Ghosh, N., Merryman, R., Lazaryan, A., Ram, R., Hertzberg, M., & Savani, B. (2024). Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission. Blood Cancer Journal, 14(1), 1–7. https://doi.org/10.1038/s41408-024-01084-w

Chicago

Shadman, Mazyar, Kwang W. Ahn, Manmeet Kaur, Lazaros Lekakis, Amer Beitinjaneh, Madiha Iqbal, Nausheen Ahmed, et al. 2024. “Autologous Transplant vs. CAR-T Therapy in Patients with DLBCL Treated While in Complete Remission.” Blood Cancer Journal 14 (1): 1–7. doi:10.1038/s41408-024-01084-w.